dermactu-191-nl-yumpu

More documents

Info

NIEUW MEXORYL 400 ZONNEFILTER, HET MEEST EFFECTIEVE UV-FILTER TEGEN DE MEEST VERRADERLIJKE UV-STRALEN * . WETENSCHAPPELIJKE INNOVATIE WETENSCHAPPELIJKE INNOVATIE NIEUW UV FILTER MEXORYL 400 NIEUW UV FILTER: MEXORYL 400 UV FILTER ABSORBTIE ABSORPTIE SPECTRUM ABSORPTIE UVB KORTE UVA LANGE UVA ANDERE FILTERS ULTRA LANGE UVA Absorptiepiek mexoryl Mexoryl 400 bij 385nm MEXORYL 400 290 320 340 380 400nm GOLFLENGTE ANTHELIOS UVMUNE 400 HELPT TE BESCHERMEN TEGEN CELSCHADE DOOR DE ZON, OXIDATIEVE STRESS. VERBETERT DE HUIDKWALITEIT. BREEDSPECTRUM BESCHERMING TEGEN UVB, UVA, ULTRA-LANGE UVA MIGREERT NIET IN DE OGEN VOOR DAGELIJKS GEBRUIK EN BIJ BLOOSTELLING AAN DE ZON OOK GETINT VERKRIJGBAAR. *Ultra-lange UVA straling (380-400nm)
Otezla ® 10 mg, 20 mg and 30 mg film-coated tablets 1. NAME OF THE MEDICINAL PRODUCT: Otezla 10 mg film-coated tablets. Otezla 20 mg film-coated tablets. Otezla 30 mg film-coated tablets. 2. QUA- LITATIVE AND QUANTITATIVE COMPOSITION: Otezla 10 mg film-coated tablets: Each film- coated tablet contains 10 mg of apremilast. Excipient(s) with known effect: Each film-coated tablet contains 57 mg of lactose (as lactose monohydrate). Otezla 20 mg film-coated tablets: Each film-coated tablet contains 20 mg of apremilast. Excipient(s) with known effect: Each film-coated tablet contains 114 mg of lactose (as lactose monohydrate). Otezla 30 mg film-coated tablets: Each film-coated tablet contains 30 mg of apremilast. Excipient(s) with known effect: Each film-coated tablet contains 171 mg of lactose (as lactose monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM: Film-coated tablet (tablet). Otezla 10 mg film-coated tablets: Pink, diamond shaped 10 mg film-coated tablet of 8 mm length with “APR” engraved on one side and “10” on the opposite side. Otezla 20 mg film-coated tablets: Brown, diamond shaped 20 mg film-coated tablet of 10 mm length with “APR” engraved on one side and “20” on the opposite side. Otezla 30 mg film-coated tablets: Beige, diamond shaped 30 mg film-coated tablet of 12 mm length with “APR” engraved on one side and “30” on the opposite side. 4. CLINICAL PARTICULARS: 4.1 Therapeutic indications: Psoriatic arthritis: Otezla, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy (see section 5.1). Psoriasis: Otezla is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA). Behçet’s disease: Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s disease (BD) who are candidates for systemic therapy. 4.2 Posology and method of administration: Treatment with Otezla should be initiated by specialists experienced in the diagnosis and treatment of psoriasis, psoriatic arthritis or Behçet’s disease. Posology: The recommended dose of apremilast is 30 mg taken orally twice daily, approximately 12 hours apart (morning and evening), with no food restrictions. An initial titration schedule is required as shown below in Table 1. No re-titration is required after initial titration. Table 1. Dose titration schedule: Day 1: AM: 10 mg; Day 2: AM: 10 mg. PM: 10 mg; Day 3: AM: 10 mg. PM: 20 mg; Day 4: AM: 20 mg. PM: 20 mg; Day 5: AM: 20 mg. PM: 30 mg; Day 6 & thereafter: AM: 30 mg. PM: 30 mg. If patients miss a dose, the next dose should be taken as soon as possible. If it is close to the time for their next dose, the missed dose should not be taken and the next dose should be taken at the regular time. During pivotal trials the greatest improvement was observed within the first 24 weeks of treatment for PsA and PSOR and within the first 12 weeks of treatment for BD. If a patient shows no evidence of therapeutic benefit after this time period, treatment should be reconsidered. The patient’s response to treatment should be evaluated on a regular basis. Special populations: Elderly patients: No dose adjustment is required for this patient population (see sections 4.8 and 5.2). Patients with renal impairment: No dose adjustment is needed in patients with mild and moderate renal impairment. The dose of apremilast should be reduced to 30 mg once daily in patients with severe renal impairment (creatinine clearance of less than 30 mL per minute estimated by the Cockcroft-Gault equation). For initial dose titration in this group, it is recommended that apremilast be titrated using only the AM schedule listed in Table 1 and the PM doses be skipped (see section 5.2). Patients with hepatic impairment: No dose adjustment is necessary for patients with hepatic impairment (see section 5.2). Paediatric population: The safety and efficacy of apremilast in children aged 0 to 17 years have not been established. No data are available. Method of administration: Otezla is for oral use. The film-coated tablets should be swallowed whole, and can be taken either with or without food. 4.3 Contraindications: Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1. Pregnancy (see section 4.6). 4.8 Undesirable effects: Summary of the safety profile: The most commonly reported adverse reactions with apremilast in PsA and PSOR are gastrointestinal (GI) disorders including diarrhoea (15.7%) and nausea (13.9%). The other most commonly reported adverse reactions include upper respiratory tract infections (8.4%), headache (7.9%), and tension headache (7.2%) and are mostly mild to moderate in severity. The most commonly reported adverse drug reactions with apremilast in BD are diarrhoea (41.3%), nausea (19.2%), headache (14.4%), upper respiratory tract infection (11.5%), upper abdominal pain (8.7%), vomiting (8.7%) and back pain (7.7%) and are mostly mild to moderate in severity. The gastrointestinal adverse reactions generally occurred within the first 2 weeks of treatment and usually resolved within 4 weeks. Hypersensitivity reactions are uncommonly observed (see section 4.3). Tabulated list of adverse reactions: The adverse reactions observed in patients treated with apremilast are listed below by system organ class (SOC) and frequency for all adverse reactions. Within each SOC and frequency grouping, adverse BEL-407-0823-80002- V2.0 – creation date 5th of February 2024 reactions are presented in order of decreasing seriousness. The adverse drug reactions were determined based on data from the apremilast clinical development programme and post-marketing experience. The frequencies of adverse drug APREMILAST IN PATIENTS WITH PSO or PsA with or without CARDIOMETABOLIC COMORBIDITIES 1-6 Otezla ® , the first and only oral PDE4-inhibitor on the market for patients with PSO or PsA, is well tolerated and requires no dose adjustment (except in severe renal impairment), monitoring or analytical screening. 1-3,a CHOOSE EFFICACY & SIMPLICITY 1-6 IT IS THAT SIMPLE >8 years of EXPERIENCE 9 in the treatment of Experts consider apremilast a suitable option in the treatment of the psoriatic patient *# and presence of comorbidities 1,7,8 Public price (VAT incl.) 2 OTEZLA ® 10, 20, 30 mg 27 tabl.: 337,47 € OTEZLA ® 30 mg 56 tabl.: 688,83€ reactions are those reported in the apremilast arms of the four Phase III studies in PsA (n = 1,945) or the two Phase III studies in PSOR (n = 1184), and in the phase III study in BD (n = 207) (the highest frequency from either data pool is represented in table 2). Frequencies are defined as: very common (≥ 1/10); common (≥ 1/100 to
Page 1: Nr 191 | MEI-JUNI 2024 Tweemaandeli
Page 5 and 6: 5 EDITORIAAL EUROMELANOMA: 25 JAAR
Page 7 and 8: Voor patiënten met MATIGE TOT ERNS
Page 9 and 10: NAAM VAN HET GENEESMIDDEL: Tremfya
Page 11 and 12: INNOVATIE MEDISCH HULPMIDDEL 5 MEDI
Page 13 and 14: BDD 2024 13 Acromegalie is een zeld
Page 15 and 16: BDD 2024 15 Tijdens follow-up consu
Page 17 and 18: BDD 2024 17 aanvankelijk het gevolg
Page 19 and 20: Cosentyx® P.P. Co-payment # 1 x 30
Page 21 and 22: Figuur 1: typische erythema migrans
Page 23 and 24: KORTE SAMENVATTING VAN DE PRODUCTKE
Page 25 and 26: AAD 2024 25 pigmentatie is vooral a
Page 27 and 28: EXPERT IN HAAR EN HOOFDHUID AANBEVO
Page 29 and 30: Zoek niet verder Thiamidol: onze op
Page 31 and 32: AAD 2024 31 Huidinfectie Teeninfect
Page 33 and 34: AAD 2024 33 betrokkenheid die gepaa
Page 35 and 36: INNOVATIE ANTIROUGEURS ROSAMED 1 st
Page 37 and 38: BASOSQUAMEUS CARCINOOM 37 thologisc
Page 39 and 40: BASOSQUAMEUS CARCINOOM 39 wachtklie
Page 41 and 42: REPORTAGE 41 beloop is chronisch en
Page 43 and 44: ZONNEPRODUCTEN: NIEUWIGHEDEN 43 Fig
Page 45 and 46: ZONNEPRODUCTEN: NIEUWIGHEDEN 45 Dez
Page 47 and 48: REPORTAGE 47 TRIASORB, BESCHERMING
Page 49 and 50: INNOVERENDE HUIDVERZORGING VOOR IED
Page 51 and 52: EXOMEGA ALLERGO Droge huid met neig
Page 53 and 54:
Doe mee aan een van de golfwedstrij
Page 55 and 56:
SCIENCE NEWS 55 Het ECDC is bezorgd
Page 57 and 58:
NAAM VAN HET GENEESMIDDEL: Myconail
Page 59 and 60:
REPORTAGE 59 ANTI-PIGMENT, HET GAMM
Page 61 and 62:
NAAM VAN HET GENEESMIDDEL: Minoxidi
show all

dermactu-191-nl-yumpu

Create successful ePaper yourself

Delete template?

Save as template?